Published in CMAJ on November 02, 2009
Graphical tools for network meta-analysis in STATA. PLoS One (2013) 2.66
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.95
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS One (2015) 1.40
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Curr Rheumatol Rev (2011) 1.23
Infliximab: 12 years of experience. Arthritis Res Ther (2011) 0.99
Cross-cultural validation of the Educational Needs Assessment Tool in RA in 7 European countries. BMC Musculoskelet Disord (2011) 0.97
Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials. Br J Clin Pharmacol (2013) 0.94
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ (2014) 0.92
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford) (2014) 0.91
Smoking and outcomes after knee and hip arthroplasty: a systematic review. J Rheumatol (2011) 0.90
Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One (2014) 0.89
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res Ther (2011) 0.88
Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int (2014) 0.88
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes (2014) 0.88
Advances in the treatment of rheumatoid arthritis. F1000Prime Rep (2014) 0.84
Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int (2014) 0.84
Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis. Rheumatol Int (2011) 0.83
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective. Health Econ Rev (2012) 0.82
Are Th17 cells an appropriate new target in the treatment of rheumatoid arthritis? Clin Transl Sci (2010) 0.81
Aberrant Activation of TGF-β in Subchondral Bone at the Onset of Rheumatoid Arthritis Joint Destruction. J Bone Miner Res (2015) 0.81
Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol (2015) 0.81
[The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality]. Z Rheumatol (2010) 0.78
Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. Clinicoecon Outcomes Res (2015) 0.78
Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. PLoS One (2014) 0.78
Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics (2015) 0.77
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis (2014) 0.77
The impact of steroids, methotrexate, and biologics on clinical and radiographic outcomes in patients with rheumatoid arthritis undergoing fusions at the craniovertebral junction. J Craniovertebr Junction Spine (2015) 0.76
Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence. Ther Adv Musculoskelet Dis (2014) 0.76
Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. BMJ Open (2014) 0.76
Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatol Int (2015) 0.76
Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison. Korean J Intern Med (2016) 0.75
A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis. Arthritis Res Ther (2016) 0.75
Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. Arthritis Res Ther (2016) 0.75
Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe. Rheumatol Ther (2016) 0.75
Improving patient-centred care for rheumatoid arthritis. CMAJ (2016) 0.75
Random-effects meta-analysis for systematic reviews of phase I clinical trials: Rare events and missing data. Res Synth Methods (2016) 0.75
Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate. CMAJ (2013) 0.75
Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. Int J Rheumatol (2017) 0.75
[Is it possible to compare different studies on efficacy of biologicals in patients with rheumatoid arthritis? : mixed treatment comparison as a new tool for indirect comparison of clinical studies]. Z Rheumatol (2011) 0.75
Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. Patient Prefer Adherence (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med (2007) 4.12
Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med (2006) 4.12
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 3.78
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis (2007) 3.31
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (2009) 2.61
Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics (2004) 2.45
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum (2002) 2.44
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol (2006) 1.82
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol (2007) 1.77
Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev (2009) 1.68
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum (2003) 1.64
Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev (2003) 1.63
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord (2008) 1.63
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis (2008) 1.59
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis (2006) 1.56
Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev (2015) 1.55
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis (2004) 1.53
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum (2008) 1.52
Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev (2009) 1.41
Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol (2008) 1.40
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med (2007) 1.34
Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol (2006) 1.26
Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis (2003) 1.09
Work disability in rheumatic diseases. Curr Opin Rheumatol (2007) 1.05
Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev (2005) 0.99
Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int (2007) 0.98
Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev (2002) 0.98
Quality of life in rheumatoid arthritis. Scand J Rheumatol (2005) 0.97
Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis (2006) 0.97
Generalized linear mixed models for meta-analysis. Stat Med (1999) 0.95
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol (2004) 14.06
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Retention in care: a challenge to survival with HIV infection. Clin Infect Dis (2007) 10.66
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) (2012) 9.25
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med (2007) 7.99
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Campaign to revitalise academic medicine kicks off. BMJ (2004) 6.94
Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med (2013) 6.40
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol (2009) 6.00
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol (2010) 5.78
The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis (2014) 5.19
High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study. BMJ (2010) 4.65
A systematic review of the global prevalence of low back pain. Arthritis Rheum (2012) 4.64
The Canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma. N Engl J Med (2003) 4.48
Who cares about academic medicine? BMJ (2004) 4.46
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet (2012) 4.36
Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury. JAMA (2005) 4.35
Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA (2013) 4.34
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. Ann Emerg Med (2004) 4.12
Racial and ethnic disparities in the use of health services: bias, preferences, or poor communication? J Gen Intern Med (2003) 4.11
Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med (2004) 4.09
Open letter to the leader of academic medicine. BMJ (2007) 4.06
CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ (2010) 4.03
Five futures for academic medicine. PLoS Med (2005) 3.95
Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med (2013) 3.89
Developing theory-informed behaviour change interventions to implement evidence into practice: a systematic approach using the Theoretical Domains Framework. Implement Sci (2012) 3.81
Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis. BMJ (2011) 3.69
Vertebroplasty appears no better than placebo for painful osteoporotic spinal fractures, and has potential to cause harm. Med J Aust (2009) 3.69
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2008) 3.44
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
The Canadian C-spine rule performs better than unstructured physician judgment. Ann Emerg Med (2003) 3.12
Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev (2008) 3.08
Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2003) 3.07
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition. Med Care (2002) 3.05
A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976) (2008) 2.94
Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol (2012) 2.81
What types of interventions generate inequalities? Evidence from systematic reviews. J Epidemiol Community Health (2012) 2.80
BIPHASIC Trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest. Circulation (2007) 2.80
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA (2003) 2.74
Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol (2004) 2.70
Identification of rheumatoid arthritis patients using an administrative database: a Veterans Affairs study. Arthritis Care Res (Hoboken) (2012) 2.67
Time to reconsider steroid injections in the spine? Med J Aust (2013) 2.63
Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev (2009) 2.61
Implementation of the Canadian C-Spine Rule: prospective 12 centre cluster randomised trial. BMJ (2009) 2.58
The OPALS Major Trauma Study: impact of advanced life-support on survival and morbidity. CMAJ (2008) 2.51
Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation (2010) 2.51
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev (2002) 2.49
Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol (2002) 2.47
Prospective validation of the ABCD2 score for patients in the emergency department with transient ischemic attack. CMAJ (2011) 2.45
Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments. Ann Emerg Med (2010) 2.44
Optimal defibrillation response intervals for maximum out-of-hospital cardiac arrest survival rates. Ann Emerg Med (2003) 2.42
Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum (2013) 2.42
Critical appraisal of health literacy indices revealed variable underlying constructs, narrow content and psychometric weaknesses. J Clin Epidemiol (2010) 2.39
PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS Med (2012) 2.31
A comparison of the quality of Cochrane reviews and systematic reviews published in paper-based journals. Eval Health Prof (2002) 2.29
Flossing for the management of periodontal diseases and dental caries in adults. Cochrane Database Syst Rev (2011) 2.29
Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke (2008) 2.23
Prognostic value of 64-slice cardiac computed tomography severity of coronary artery disease, coronary atherosclerosis, and left ventricular ejection fraction. J Am Coll Cardiol (2010) 2.21
Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol (2013) 2.18
The out-of-hospital validation of the Canadian C-Spine Rule by paramedics. Ann Emerg Med (2009) 2.17
Diagnostic accuracy and impact of computed tomographic coronary angiography on utilization of invasive coronary angiography. Circ Cardiovasc Imaging (2009) 2.16
Retrospective application of the NEXUS low-risk criteria for cervical spine radiography in Canadian emergency departments. Ann Emerg Med (2004) 2.15
Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail (2012) 2.13
Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA (2012) 2.13
Back pain: a National Health Priority Area in Australia? Med J Aust (2009) 2.11
Power and color Doppler ultrasound settings for inflammatory flow: impact on scoring of disease activity in patients with rheumatoid arthritis. Arthritis Rheumatol (2015) 2.10
Prognostic value of CT angiography in coronary bypass patients. JACC Cardiovasc Imaging (2011) 2.10
Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv (2012) 2.07
Canada urgently needs a national network of libraries to access evidence. Healthc Q (2006) 2.07
Multicentre prospective validation of use of the Canadian C-Spine Rule by triage nurses in the emergency department. CMAJ (2010) 2.07
The grounded psychometric development and initial validation of the Health Literacy Questionnaire (HLQ). BMC Public Health (2013) 2.06
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med (2003) 2.04
Magnetic resonance imaging, magnetic resonance arthrography and ultrasonography for assessing rotator cuff tears in people with shoulder pain for whom surgery is being considered. Cochrane Database Syst Rev (2013) 2.03
A prospective cohort study of patients with transient ischemic attack to identify high-risk clinical characteristics. Stroke (2013) 2.03